This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: GenVec

Craig P. writes, " Seems like the J.P. Morgan Healthcare Conference was nothing but a lot of junk this year. No real news. Probably just another excuse of a conference for J.P. Morgan to entice biotech companies to rob their shareholders blind with more dilutive financings."

C'mon Craig, let's be fair. Biotech CEOs don't need bankers like J.P. Morgan to push them into dilutive financings. They're very happy to do so on their own accord!

Craig is right, the biotech tribe's insanely busy gathering in San Francisco last week did not produce much news, and that was a disappointment. Yet optimism for the biotech sector and the year ahead did seem high. That's a plus, I guess. Of course, those that attended were the Kool-Aid drinkers -- convincing investors who were not in attendance to put money to work in biotech is the real trick.

I'm still working through my notes from last week and doing more research, but some of the stock stories which left me with the warm fuzzies were Medivation (MDVN - Get Report) (I think the Alzheimer's drug Dimebon has a real shot at working); Alkermes (ALKS - Get Report) (a good way to play the FDA's upcoming decision on Exenatide Once Weekly); Gilead Sciences (GILD) (HIV, HIV, HIV); and even Genzyme (GENZ) (I think investors are going to kick out the CEO, Henri Termeer).

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
7 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ANX $0.73 0.00%
ALKS $61.35 -0.73%
CYCC $0.80 -2.28%
DNDN $0.06 -6.02%
EXAS $26.20 4.34%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs